Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells

I. Hermanova, A. Arruabarrena-Aristorena, K. Valis, H. Nuskova, M. Alberich-Jorda, K. Fiser, S. Fernandez-Ruiz, D. Kavan, A. Pecinova, M. Niso-Santano, M. Zaliova, P. Novak, J. Houstek, T. Mracek, G. Kroemer, A. Carracedo, J. Trka, J. Starkova,

. 2016 ; 30 (1) : 209-218. [pub] 20150804

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16020449

Grant support
NT12429 MZ0 CEP Register
NT12370 MZ0 CEP Register

l-asparaginase (ASNase), a key component in the treatment of childhood acute lymphoblastic leukemia (ALL), hydrolyzes plasma asparagine and glutamine and thereby disturbs metabolic homeostasis of leukemic cells. The efficacy of such therapeutic strategy will depend on the capacity of cancer cells to adapt to the metabolic challenge, which could relate to the activation of compensatory metabolic routes. Therefore, we studied the impact of ASNase on the main metabolic pathways in leukemic cells. Treating leukemic cells with ASNase increased fatty-acid oxidation (FAO) and cell respiration and inhibited glycolysis. FAO, together with the decrease in protein translation and pyrimidine synthesis, was positively regulated through inhibition of the RagB-mTORC1 pathway, whereas the effect on glycolysis was RagB-mTORC1 independent. As FAO has been suggested to have a pro-survival function in leukemic cells, we tested its contribution to cell survival following ASNase treatment. Pharmacological inhibition of FAO significantly increased the sensitivity of ALL cells to ASNase. Moreover, constitutive activation of the mammalian target of rapamycin pathway increased apoptosis in leukemic cells treated with ASNase, but did not increase FAO. Our study uncovers a novel therapeutic option based on the combination of ASNase and FAO inhibitors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020449
003      
CZ-PrNML
005      
20190820111023.0
007      
ta
008      
160722s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/leu.2015.213 $2 doi
024    7_
$a 10.1038/leu.2015.213 $2 doi
035    __
$a (PubMed)26239197
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Heřmanová, Ivana $u CLIP-Childhood Leukaemia Investigation Prague, Department of Pediatric Hematology/Oncology, Charles University Prague, Prague, Czech Republic. $7 xx0231628
245    10
$a Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells / $c I. Hermanova, A. Arruabarrena-Aristorena, K. Valis, H. Nuskova, M. Alberich-Jorda, K. Fiser, S. Fernandez-Ruiz, D. Kavan, A. Pecinova, M. Niso-Santano, M. Zaliova, P. Novak, J. Houstek, T. Mracek, G. Kroemer, A. Carracedo, J. Trka, J. Starkova,
520    9_
$a l-asparaginase (ASNase), a key component in the treatment of childhood acute lymphoblastic leukemia (ALL), hydrolyzes plasma asparagine and glutamine and thereby disturbs metabolic homeostasis of leukemic cells. The efficacy of such therapeutic strategy will depend on the capacity of cancer cells to adapt to the metabolic challenge, which could relate to the activation of compensatory metabolic routes. Therefore, we studied the impact of ASNase on the main metabolic pathways in leukemic cells. Treating leukemic cells with ASNase increased fatty-acid oxidation (FAO) and cell respiration and inhibited glycolysis. FAO, together with the decrease in protein translation and pyrimidine synthesis, was positively regulated through inhibition of the RagB-mTORC1 pathway, whereas the effect on glycolysis was RagB-mTORC1 independent. As FAO has been suggested to have a pro-survival function in leukemic cells, we tested its contribution to cell survival following ASNase treatment. Pharmacological inhibition of FAO significantly increased the sensitivity of ALL cells to ASNase. Moreover, constitutive activation of the mammalian target of rapamycin pathway increased apoptosis in leukemic cells treated with ASNase, but did not increase FAO. Our study uncovers a novel therapeutic option based on the combination of ASNase and FAO inhibitors.
650    _2
$a asparaginasa $x terapeutické užití $7 D001215
650    _2
$a autofagie $x účinky léků $7 D001343
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a mastné kyseliny $x metabolismus $7 D005227
650    _2
$a lidé $7 D006801
650    _2
$a monomerní proteiny vázající GTP $x fyziologie $7 D020559
650    _2
$a multiproteinové komplexy $x fyziologie $7 D046912
650    _2
$a oxidace-redukce $7 D010084
650    _2
$a akutní lymfatická leukemie $x farmakoterapie $x metabolismus $x patologie $7 D054198
650    _2
$a pyrimidiny $x biosyntéza $7 D011743
650    _2
$a TOR serin-threoninkinasy $x fyziologie $7 D058570
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Arruabarrena-Aristorena, A $u CIC bioGUNE Technology Park of Bizkaia, Derio, Spain. $7 gn_A_00008904
700    1_
$a Vališ, Karel $u Laboratory of Structural Biology and Cell Signaling, Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Department of Biochemistry, Charles University, Prague, Czech Republic. $7 _AN058828
700    1_
$a Nůsková, Hana $u Department of Bioenergetics, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic. $7 xx0118111
700    1_
$a Alberich-Jorda, Meritxell, $u Laboratory of Molecular Immunology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic. $d 1975- $7 xx0205681
700    1_
$a Fišer, Karel $u CLIP-Childhood Leukaemia Investigation Prague, Department of Pediatric Hematology/Oncology, Charles University Prague, Prague, Czech Republic. $7 xx0116772
700    1_
$a Fernandez-Ruiz, S $u CIC bioGUNE Technology Park of Bizkaia, Derio, Spain.
700    1_
$a Kavan, Daniel, $u Laboratory of Structural Biology and Cell Signaling, Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Department of Biochemistry, Charles University, Prague, Czech Republic. $d 1977- $7 xx0128917
700    1_
$a Pecinová, Alena $u Department of Bioenergetics, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic. $7 xx0167913
700    1_
$a Niso-Santano, M $u Equipe 11 labellisée par la Ligue Nationale Contre le Cancer; INSERM U1138; Centre de Recherche des Cordeliers, Paris, France. Metabolomics and Molecular Cell Biology Platforms; Gustave Roussy, Villejuif, France.
700    1_
$a Zaliova, M $u CLIP-Childhood Leukaemia Investigation Prague, Department of Pediatric Hematology/Oncology, Charles University Prague, Prague, Czech Republic.
700    1_
$a Novak, P $u Laboratory of Structural Biology and Cell Signaling, Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Department of Biochemistry, Charles University, Prague, Czech Republic.
700    1_
$a Houštěk, Josef, $u Department of Bioenergetics, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic. $d 1947- $7 xx0030591
700    1_
$a Mráček, Tomáš $u Department of Bioenergetics, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic. $7 xx0122128
700    1_
$a Kroemer, G $u Equipe 11 labellisée par la Ligue Nationale Contre le Cancer; INSERM U1138; Centre de Recherche des Cordeliers, Paris, France. Metabolomics and Molecular Cell Biology Platforms; Gustave Roussy, Villejuif, France. Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP, Paris, France. Université Paris Descartes; Sorbonne Paris Cité, Paris, France.
700    1_
$a Carracedo, A $u CIC bioGUNE Technology Park of Bizkaia, Derio, Spain. Ikerbasque, Basque Foundation for Science, Bilbao, Spain. Department of Biochemistry and Molecular biology, University of the Basque Country, Leioa, Spain.
700    1_
$a Trka, Jan, $u CLIP-Childhood Leukaemia Investigation Prague, Department of Pediatric Hematology/Oncology, Charles University Prague, Prague, Czech Republic. University Hospital Motol, Prague, Czech Republic. $d 1966- $7 xx0036261
700    1_
$a Starková, Júlia, $u CLIP-Childhood Leukaemia Investigation Prague, Department of Pediatric Hematology/Oncology, Charles University Prague, Prague, Czech Republic. $d 1977- $7 xx0106984
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 30, č. 1 (2016), s. 209-218
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26239197 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20190820111258 $b ABA008
999    __
$a ok $b bmc $g 1155119 $s 944977
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 30 $c 1 $d 209-218 $e 20150804 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
GRA    __
$a NT12429 $p MZ0
GRA    __
$a NT12370 $p MZ0
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Archiving options